An Open Label Extension Study of the Efficacy of MORAb-003
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Susan Weil, MD
Morphotek
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Nationales Centrum Fur Tumorerkrandungen
Heidelberg, Germany
- Sharp Memorial Hospital
Chula Vista, California, United States
- South Texas Oncology & Hematology
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Jan 2010
- Primary completion
- 5 Mar 2013
- Completion
- 5 Mar 2013
- Last update posted
- 8 Dec 2021
- Registered enrollment
- 3
- Registry id
- NCT01018563
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.